Organon (OGN) Non-Current Debt (2021 - 2026)
Organon (OGN) posted quarterly Non-Current Debt of $8.6 billion for Q2 2026, down 3.86% year-over-year from $8.9 billion in Q2 2025, and little changed on a QoQ basis from $8.6 billion in Q1 2026.
Organon (OGN) Non-Current Debt (2021 - 2026) Analysis & Trends
Organon has reported Non-Current Debt for 6 years, with the latest figure at $8.6 billion in Q2 2026.
- Non-Current Debt for Q2 2026 came in at $8.6 billion, down 3.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.6 billion (down 3.86% YoY), and the FY2025 annual result was $8.6 billion, down 2.66% from the prior year.
- Non-Current Debt steadied at $8.6 billion in Q2 2026, from $8.6 billion in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.1 billion in Q1 2022 and troughed at $8.6 billion in Q2 2026.
- A 5-year average of $8.8 billion and a median of $8.7 billion in 2023 frame the typical range for Non-Current Debt.
- The widest annual swing landed in 2022, when Non-Current Debt decreased 6.46%; it then gained 2.78% in 2025.
- A 5-year view of Non-Current Debt shows it stood at $8.9 billion in 2022, then dropped by 1.82% to $8.8 billion in 2023, then advanced by 1.47% to $8.9 billion in 2024, then dropped by 2.66% to $8.6 billion in 2025, then decreased by 1.05% to $8.6 billion in 2026.
- Per Business Quant data, the three most recent Non-Current Debt figures were $8.6 billion in Q2 2026, $8.6 billion in Q1 2026, and $8.6 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 37.34 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 62.48 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 51.08 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 23.68 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 57.30 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 26.25 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 60.50 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -18.71 Bn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn | 8.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.55 Bn |
| Mar 31, 2026 | 8.57 Bn |
| Dec 31, 2025 | 8.63 Bn |
| Sep 30, 2025 | 8.78 Bn |
| Jun 30, 2025 | 8.90 Bn |
| Mar 31, 2025 | 8.96 Bn |
| Dec 31, 2024 | 8.86 Bn |
| Sep 30, 2024 | 8.75 Bn |
| Jun 30, 2024 | 8.66 Bn |
| Mar 31, 2024 | 8.71 Bn |
| Dec 31, 2023 | 8.75 Bn |
| Sep 30, 2023 | 8.65 Bn |
| Jun 30, 2023 | 8.72 Bn |
| Mar 31, 2023 | 8.70 Bn |
| Dec 31, 2022 | 8.91 Bn |
| Sep 30, 2022 | 8.70 Bn |
| Jun 30, 2022 | 8.89 Bn |
| Mar 31, 2022 | 9.09 Bn |
| Dec 31, 2021 | 9.13 Bn |
| Sep 30, 2021 | 9.30 Bn |